Daclatasvir (Daklinza) for HCV genotype 3 infection

Med Lett Drugs Ther. 2015 Oct 12;57(1479):142-3.

Abstract

Daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) is the first all-oral, interferon- and ribavirin-free drug regimen for treatment of hepatitis C virus genotype 3 infection. This combination is effective and convenient, but it is very expensive.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / administration & dosage*
  • Carbamates
  • Clinical Trials as Topic / methods
  • Drug Therapy, Combination
  • Genotype*
  • Hepacivirus / drug effects*
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy*
  • Humans
  • Imidazoles / administration & dosage*
  • Pyrrolidines
  • Sofosbuvir / administration & dosage*
  • Valine / analogs & derivatives

Substances

  • Antiviral Agents
  • Carbamates
  • Imidazoles
  • Pyrrolidines
  • Valine
  • daclatasvir
  • Sofosbuvir